Vik Chopra
Stock Analyst at Wells Fargo
(1.57)
# 3,308
Out of 4,944 analysts
47
Total ratings
30%
Success rate
-9.7%
Average return
Main Sectors:
Stocks Rated by Vik Chopra
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMED Globus Medical | Maintains: Overweight | $76 → $66 | $61.87 | +6.68% | 10 | Aug 8, 2025 | |
| ENOV Enovis | Maintains: Overweight | $48 → $41 | $28.75 | +42.61% | 4 | Aug 8, 2025 | |
| SOLV Solventum | Maintains: Equal-Weight | $75 → $79 | $72.09 | +9.59% | 4 | Aug 8, 2025 | |
| XRAY DENTSPLY SIRONA | Maintains: Equal-Weight | $16 → $15 | $13.05 | +14.94% | 3 | Aug 8, 2025 | |
| NVST Envista Holdings | Maintains: Equal-Weight | $17 → $19 | $20.89 | -9.05% | 3 | Aug 1, 2025 | |
| ALGN Align Technology | Maintains: Overweight | $246 → $199 | $140.49 | +41.65% | 3 | Jul 31, 2025 | |
| MASI Masimo | Maintains: Overweight | $205 → $190 | $150.13 | +26.56% | 9 | May 7, 2025 | |
| IART Integra LifeSciences Holdings | Maintains: Equal-Weight | $25 → $13 | $13.77 | -5.59% | 2 | May 6, 2025 | |
| HSIC Henry Schein | Maintains: Equal-Weight | $80 → $75 | $67.52 | +11.08% | 2 | May 6, 2025 | |
| CNMD CONMED | Maintains: Equal-Weight | $70 → $57 | $54.01 | +5.54% | 4 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $13 | $9.13 | +42.39% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $19 | $15.72 | +20.87% | 1 | Aug 1, 2024 |
Globus Medical
Aug 8, 2025
Maintains: Overweight
Price Target: $76 → $66
Current: $61.87
Upside: +6.68%
Enovis
Aug 8, 2025
Maintains: Overweight
Price Target: $48 → $41
Current: $28.75
Upside: +42.61%
Solventum
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $75 → $79
Current: $72.09
Upside: +9.59%
DENTSPLY SIRONA
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $13.05
Upside: +14.94%
Envista Holdings
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $17 → $19
Current: $20.89
Upside: -9.05%
Align Technology
Jul 31, 2025
Maintains: Overweight
Price Target: $246 → $199
Current: $140.49
Upside: +41.65%
Masimo
May 7, 2025
Maintains: Overweight
Price Target: $205 → $190
Current: $150.13
Upside: +26.56%
Integra LifeSciences Holdings
May 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $13
Current: $13.77
Upside: -5.59%
Henry Schein
May 6, 2025
Maintains: Equal-Weight
Price Target: $80 → $75
Current: $67.52
Upside: +11.08%
CONMED
May 1, 2025
Maintains: Equal-Weight
Price Target: $70 → $57
Current: $54.01
Upside: +5.54%
Nov 13, 2024
Maintains: Overweight
Price Target: $15 → $13
Current: $9.13
Upside: +42.39%
Aug 1, 2024
Maintains: Overweight
Price Target: $26 → $19
Current: $15.72
Upside: +20.87%